Omniscan (Gadodiamide)

Gadodiamide, the active ingredient in Omniscan, is a gadolinium‑based contrast agent presented as an injection solution for intravenous use. It enhances magnetic resonance imaging by shortening T1 relaxation time, allowing clearer visualization of brain, spine and other body structures. GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Omniscan (gadodiamide) is employed as a contrast agent in magnetic resonance imaging to improve visualization of anatomical structures.

- Magnetic resonance imaging (MRI) of the brain, spine, and other body parts: provides enhanced signal intensity to aid detection of lesions. - Magnetic resonance angiography (MRA): improves visualization of vascular structures for diagnostic assessment. - Contrast enhancement for detection of lesions and vascular structures: facilitates differentiation between normal and pathological tissue.

Adverse reactions may occur following intravenous administration of gadodiamide.

Common Side Effects: - Nausea: mild to moderate discomfort after injection. - Headache: transient pain often reported during or after the procedure. - Injection site pain or warmth: sensation at the site of administration. - Metallic taste: brief taste alteration during infusion. - Dizziness: occasional light‑headedness post‑dose. - Flushing: temporary skin reddening.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Nephrogenic systemic fibrosis (NSF): rare fibrotic condition in patients with severe renal impairment. - Severe hypotension: sudden drop in blood pressure after injection. - Cardiac arrest: extremely rare but life‑threatening event. - Seizures: uncommon neurologic reaction. - Acute kidney injury: potential renal function decline in susceptible individuals.

Careful assessment and monitoring are required when using gadodiamide.

- Assess renal function: evaluate glomerular filtration rate before administration. - Screen for prior contrast reactions: avoid if the patient has a history of severe allergy to gadolinium agents. - Use the lowest effective dose: follow imaging protocol recommendations. - Monitor for immediate reactions: observe the patient for at least 30 minutes after injection. - Avoid in patients with severe renal impairment: consider alternative imaging strategies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Gadodiamide may interact with other drugs that affect renal function or gadolinium handling.

Major Interactions (Avoid): - Renal toxic drugs (e.g., high‑dose aminoglycosides): increase risk of nephrogenic systemic fibrosis. - Concurrent use of other gadolinium agents: cumulative gadolinium load may heighten toxicity. - Iron chelators (e.g., deferoxamine): may disrupt gadolinium binding and increase free gadolinium.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance of gadodiamide. - NSAIDs: can affect renal function, requiring closer observation. - Other contrast agents (iodinated or MRI): schedule appropriate spacing to reduce combined renal stress.